FSTX - F-star Therapeutics sale to Sino-Biopharma withdrawn refiled with CFIUS

• F-star Therapeutics ( NASDAQ: FSTX ) planned sale to Sino-Biopharma was withdrawn and refiled with CFIUS.
• CFIUS’s acceptance of the refiled voluntary notice is effective as of Wednesday, F-star ( FSTX ) said in an 8-K filing. CFIUS will have a review period of up to 45 calendar days, subject to a further 45 calendar days if extended. Currently the F-star sale to Sino-Biopharma has a Nov. 18 termination date, where either of the parties can walk from the deal unless the parties mutually agree to extend the date.
• F-star ( FSTX ) said it believes that this “pull and refile” procedure has been requested to enable CFIUS more time to determine whether and to what extent any mitigation steps should be taken.
• The disclosure comes as F-star Therapeutics dropped over the past two trading sessions on investor concern about the national security review of the deal.

For further details see: